Home › Companies › Halozyme Therapeutics, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Halozyme Therapeutics, Inc.’s Form 8-K, filed 2026-05-07 (Item 5.07 on EDGAR). Page generated 04 October 2026.
Explore Halozyme Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Halozyme Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-05-07 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Bernadette Connaughton | 89,053,734 | 5,068,160 | 127,131 | -- | 9,889,219 | Majority: yes |
| Elect Director: Matthew L. Posard | 82,739,433 | 10,236,878 | 1,272,714 | -- | 9,889,219 | Majority: yes |
| Proposal 2: The advisory vote on the compensation of the Company's named executive officers was as follows: | 84,682,518 | 9,311,426 | 255,081 | -- | 9,889,219 | Passed |
| Proposal 3: The vote on a proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was as follows: | 103,197,579 | 849,433 | 91,232 | -- | -- | Passed |
Source: Halozyme Therapeutics, Inc., Form 8-K, filed with the SEC on 2026-05-07 — read the filing on EDGAR.
Each item below shows how the 597 asset managers that disclosed a Halozyme Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Halozyme Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Meeting held 2026-05-05.
Combines 15 wordings of this item as funds reported it.
90% Passed · of votes cast
Halozyme Therapeutics, Inc.’s own tally for this item (“Proposal 2: The advisory vote on the compensation of the Company's named executive officers was as follows:”): 84,682,518 for, 9,311,426 against — passed, per its Form 8-K filed 2026-05-07 (Item 5.07). Of all 118,523,000 outstanding shares: 71% for, 8% against (79% of the company cast a for/against vote).
The 594 asset managers below cast 93% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 12,356,311 | 10 | 0 | 0 | For |
| BlackRock | 10,855,234 | 1,579 | 0 | 0 | For |
| Invesco | 5,427,831 | 0 | 0 | 0 | For |
| State Street | 74,335 | 4,726,429 | 0 | 0 | Against |
| Federated Hermes | 2,648,014 | 0 | 0 | 0 | For |
| Charles Schwab | 2,534,323 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,468,793 | 0 | 0 | 0 | For |
| Fidelity | 2,444,015 | 0 | 0 | 0 | For |
| SNYDER CAPITAL MANAGEMENT L P | 2,153,875 | 0 | 0 | 0 | For |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 2,098,221 | 0 | 0 | 0 | For |
| Boston Partners | 2,028,881 | 0 | 0 | 0 | For |
| AllianceBernstein | 1,936,298 | 0 | 0 | 0 | For |
| Janus Henderson | 1,845,794 | 0 | 0 | 0 | For |
| Capital Group | 1,660,770 | 0 | 0 | 0 | For |
| JUPITER ASSET MANAGEMENT LTD | 1,567,242 | 0 | 0 | 0 | For |
| First Trust | 1,501,100 | 0 | 0 | 0 | For |
| Putnam | 1,408,002 | 0 | 0 | 0 | For |
| John Hancock | 1,387,812 | 0 | 0 | 0 | For |
| FULLER & THALER ASSET MANAGEMENT, INC. | 1,344,686 | 0 | 0 | 0 | For |
| GW&K Investment Management, LLC | 228,358 | 0 | 0 | 0 | Split |
| CONGRESS ASSET MANAGEMENT CO | 1,200,563 | 0 | 0 | 0 | For |
| NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST | 1,125,605 | 0 | 0 | 0 | For |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 1,095,740 | 0 | 0 | 0 | For |
| Northern Trust | 1,019,691 | 0 | 0 | 0 | For |
| Stephens Investment Management Group LLC | 1,005,872 | 0 | 0 | 0 | For |
Showing the 25 largest of 594 asset managers. See all 594 in the interactive database.
Meeting held 2026-05-05.
Combines 4 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Halozyme Therapeutics, Inc.’s own tally for this item (“Elect Director: Bernadette Connaughton”): 89,053,734 for, 5,068,160 against, per its Form 8-K filed 2026-05-07 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 118,523,000 outstanding shares: 75% for, 4% against (79% of the company cast a for/against vote).
The 143 asset managers below cast 97% of the shares they voted on this item FOR (45,052,087 for, 1,629,505 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 11,406,613 | 11 | 0 | 0 | For |
| BlackRock | 7,468,246 | 0 | 0 | 0 | For |
| Fidelity | 2,427,364 | 0 | 0 | 0 | For |
| Invesco | 2,371,379 | 0 | 0 | 0 | For |
| State Street | 2,337,907 | 0 | 0 | 0 | For |
| First Trust | 1,491,893 | 0 | 0 | 0 | For |
| John Hancock | 137,158 | 1,168,773 | 0 | 0 | Against |
| Charles Schwab | 1,257,706 | 0 | 0 | 0 | For |
| Federated Hermes | 1,113,851 | 0 | 0 | 0 | For |
| Capitol Series Trust | 898,255 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 875,241 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 849,734 | 0 | 0 | 0 | For |
| Capital Group | 830,385 | 0 | 0 | 0 | For |
| Putnam | 561,194 | 0 | 0 | 0 | For |
| TIAA | 551,184 | 0 | 0 | 0 | For |
| Dimensional | 521,318 | 0 | 0 | 0 | For |
| WILLIAM BLAIR FUNDS | 433,965 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 313,876 | 101,043 | 0 | 0 | For |
| Jackson National | 407,549 | 0 | 0 | 0 | For |
| Nationwide | 380,986 | 0 | 0 | 0 | For |
| EA Series Trust | 379,284 | 0 | 0 | 0 | For |
| Calamos | 349,930 | 0 | 0 | 0 | For |
| PROFESSIONALLY MANAGED PORTFOLIOS | 347,050 | 0 | 0 | 0 | For |
| Victory Capital | 325,289 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 321,070 | 0 | 0 | 0 | For |
Showing the 25 largest of 143 asset managers. See all 143 in the interactive database.
Meeting held 2026-05-05.
Combines 5 wordings of this item as funds reported it.
89% Majority: yes · of votes cast
Halozyme Therapeutics, Inc.’s own tally for this item (“Elect Director: Matthew L. Posard”): 82,739,433 for, 10,236,878 against, per its Form 8-K filed 2026-05-07 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 118,523,000 outstanding shares: 70% for, 9% against (78% of the company cast a for/against vote).
The 143 asset managers below cast 91% of the shares they voted on this item FOR (42,500,283 for, 4,181,306 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 11,400,139 | 6,482 | 3 | 0 | For |
| BlackRock | 7,468,246 | 0 | 0 | 0 | For |
| Fidelity | 2,427,364 | 0 | 0 | 0 | For |
| Invesco | 2,371,379 | 0 | 0 | 0 | For |
| State Street | 20,564 | 2,317,343 | 0 | 0 | Against |
| First Trust | 1,491,893 | 0 | 0 | 0 | For |
| John Hancock | 137,158 | 1,168,773 | 0 | 0 | Against |
| Charles Schwab | 1,257,706 | 0 | 0 | 0 | For |
| Federated Hermes | 1,113,851 | 0 | 0 | 0 | For |
| Capitol Series Trust | 898,255 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 875,241 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 849,734 | 0 | 0 | 0 | For |
| Capital Group | 830,385 | 0 | 0 | 0 | For |
| Putnam | 561,194 | 0 | 0 | 0 | For |
| TIAA | 551,184 | 0 | 0 | 0 | For |
| Dimensional | 521,318 | 0 | 0 | 0 | For |
| WILLIAM BLAIR FUNDS | 433,965 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 313,876 | 101,043 | 0 | 0 | For |
| Jackson National | 407,549 | 0 | 0 | 0 | For |
| Nationwide | 380,986 | 0 | 0 | 0 | For |
| EA Series Trust | 379,284 | 0 | 0 | 0 | For |
| Calamos | 349,930 | 0 | 0 | 0 | For |
| PROFESSIONALLY MANAGED PORTFOLIOS | 347,050 | 0 | 0 | 0 | For |
| Victory Capital | 325,289 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 321,070 | 0 | 0 | 0 | For |
Showing the 25 largest of 143 asset managers. See all 143 in the interactive database.
Meeting held 2026-05-05.
Combines 4 wordings of this item as funds reported it.
99.1% Passed · of votes cast
Halozyme Therapeutics, Inc.’s own tally for this item (“Proposal 3: The vote on a proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was as follows:”): 103,197,579 for, 849,433 against — passed, per its Form 8-K filed 2026-05-07 (Item 5.07). Of all 118,523,000 outstanding shares: 87% for, 0.8% against (88% of the company cast a for/against vote).
The 143 asset managers below cast 99.9% of the shares they voted on this item FOR (46,674,990 for, 6,602 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 11,400,153 | 6,471 | 0 | 0 | For |
| BlackRock | 7,468,246 | 0 | 0 | 0 | For |
| Fidelity | 2,427,364 | 0 | 0 | 0 | For |
| Invesco | 2,371,379 | 0 | 0 | 0 | For |
| State Street | 2,337,798 | 109 | 0 | 0 | For |
| First Trust | 1,491,893 | 0 | 0 | 0 | For |
| John Hancock | 1,305,931 | 0 | 0 | 0 | For |
| Charles Schwab | 1,257,706 | 0 | 0 | 0 | For |
| Federated Hermes | 1,113,851 | 0 | 0 | 0 | For |
| Capitol Series Trust | 898,255 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 875,241 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 849,734 | 0 | 0 | 0 | For |
| Capital Group | 830,385 | 0 | 0 | 0 | For |
| Putnam | 561,194 | 0 | 0 | 0 | For |
| TIAA | 551,184 | 0 | 0 | 0 | For |
| Dimensional | 521,318 | 0 | 0 | 0 | For |
| WILLIAM BLAIR FUNDS | 433,965 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 414,919 | 0 | 0 | 0 | For |
| Jackson National | 407,549 | 0 | 0 | 0 | For |
| Nationwide | 380,986 | 0 | 0 | 0 | For |
| EA Series Trust | 379,284 | 0 | 0 | 0 | For |
| Calamos | 349,930 | 0 | 0 | 0 | For |
| PROFESSIONALLY MANAGED PORTFOLIOS | 347,050 | 0 | 0 | 0 | For |
| Victory Capital | 325,289 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 321,070 | 0 | 0 | 0 | For |
Showing the 25 largest of 143 asset managers. See all 143 in the interactive database.
Meeting held 2025-05-01 (outside the 2025-2026 season's 1 July to 30 June window; reported in this season's filings).
96% Passed · of votes cast
Halozyme Therapeutics, Inc.’s own tally for this item (“Proposal 2: The advisory vote on the compensation of the Company's named executive officers was as follows:”): 98,252,464 for, 3,966,034 against — passed, per its Form 8-K filed 2025-05-02 (Item 5.07). Of all 118,523,000 outstanding shares: 83% for, 3% against (86% of the company cast a for/against vote).
The 2 asset managers below cast 100% of the shares they voted on this item FOR (399,901 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| GLENMEDE FUND INC | 386,531 | 0 | 0 | 0 | For |
| Hodges Capital Management Inc. | 13,370 | 0 | 0 | 0 | For |
Meeting held 2026-05-05.
All nominees (reported as one line). These filers reported the election of directors as a single line covering every nominee. It is not attributed to any one director, and no share total is shown for it.
100% fund support · no official result
The 2 asset managers below cast 100% of the shares they voted on this item FOR.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| NORTHERN LIGHTS FUND TRUST II | 19,583 | 0 | 0 | 0 | For |
| TEALWOOD ASSET MANAGEMENT INC | 10,726 | 0 | 0 | 0 | For |
Meeting held 2026-05-05.
99.1% Passed · of votes cast
Halozyme Therapeutics, Inc.’s own tally for this item (“Proposal 3: The vote on a proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was as follows:”): 103,197,579 for, 849,433 against — passed, per its Form 8-K filed 2026-05-07 (Item 5.07). Of all 118,523,000 outstanding shares: 87% for, 0.8% against (88% of the company cast a for/against vote).
The 2 asset managers below cast 100% of the shares they voted on this item FOR (30,309 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| NORTHERN LIGHTS FUND TRUST II | 19,583 | 0 | 0 | 0 | For |
| TEALWOOD ASSET MANAGEMENT INC | 10,726 | 0 | 0 | 0 | For |
Ranked by the number of Halozyme Therapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 118,523,000 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 10.43% |
| 2 | BlackRock | 9.16% |
| 3 | Invesco | 4.58% |
| 4 | State Street | 4.05% |
| 5 | Federated Hermes | 2.23% |
| 6 | Charles Schwab | 2.14% |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 2.08% |
| 8 | Fidelity | 2.06% |
| 9 | SNYDER CAPITAL MANAGEMENT L P | 1.82% |
| 10 | WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 1.77% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| BlackRock | 11.19% | 13F |
| Vanguard Group | 9.76% | 13F |
| State Street Corporation | 5.11% | DEF14A |
| Invesco | 3.39% | 13F |
| Morgan Stanley | 2.24% | 13F |
| Helen I. Torley | 1.86% | DEF14A |
| Dimensional Fund Advisors | 1.75% | 13F |
| D.E. Shaw | 1.60% | 13F |
| Two Sigma | 1.34% | 13F |
| Charles Schwab | 1.09% | 13F |
Percentages above are of 118,523,000 shares outstanding, as reported by Halozyme Therapeutics, Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Halozyme Therapeutics, Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.
At Halozyme Therapeutics, Inc.'s shareholder meeting held 2026-05-05, in the 2025-2026 proxy season, 597 asset managers reported how they voted in their SEC Form N-PX filings, covering 2,951 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, by a non-binding advisory vote, the compensation of the Company's named executive… — the proposal passed with 90% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Halozyme Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-05-07.
Halozyme Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).